Brief: Tonix Pharmaceuticals Announces First Patient Enrolled In Phase 2 Catalyst Study Of Tnx-1300 For Treatment Of Cocaine Intoxication
20/08/2024 12:34
Aug 20 (Reuters) - Tonix Pharmaceuticals Holding Corp
TNXP.O :
* TONIX PHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED IN
PHASE
2 CATALYST STUDY OF TNX-1300 FOR THE TREATMENT OF COCAINE
INTOXICATION
* TONIX PHARMACEUTICALS HOLDING CORP - EXPECTS TOPLINE
RESULTS IN
H1 2025
Source text for Eikon: ID:nGNXbKVVZb
Further company coverage: TNXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview